MX351659B - Non-aqueous high concentration reduced viscosity suspension formulations of antibodies. - Google Patents

Non-aqueous high concentration reduced viscosity suspension formulations of antibodies.

Info

Publication number
MX351659B
MX351659B MX2013010335A MX2013010335A MX351659B MX 351659 B MX351659 B MX 351659B MX 2013010335 A MX2013010335 A MX 2013010335A MX 2013010335 A MX2013010335 A MX 2013010335A MX 351659 B MX351659 B MX 351659B
Authority
MX
Mexico
Prior art keywords
antibodies
high concentration
reduced viscosity
suspension formulations
aqueous high
Prior art date
Application number
MX2013010335A
Other languages
Spanish (es)
Other versions
MX2013010335A (en
Inventor
Kui Liu
Weiguo Dai
Beth Hill
Carl Mieczkowski
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of MX2013010335A publication Critical patent/MX2013010335A/en
Publication of MX351659B publication Critical patent/MX351659B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Mycology (AREA)
  • Dispersion Chemistry (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Inorganic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present invention relates to non-aqueous high concentration reduced viscosity suspension formulations antibodies and methods of making and using them.
MX2013010335A 2011-03-09 2011-09-30 Non-aqueous high concentration reduced viscosity suspension formulations of antibodies. MX351659B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13/043,925 US20110223208A1 (en) 2010-03-09 2011-03-09 Non-Aqueous High Concentration Reduced Viscosity Suspension Formulations
PCT/US2011/054257 WO2012121754A1 (en) 2011-03-09 2011-09-30 Non-aqueous high concentration reduced viscosity suspension formulations of antibodies

Publications (2)

Publication Number Publication Date
MX2013010335A MX2013010335A (en) 2013-10-03
MX351659B true MX351659B (en) 2017-10-23

Family

ID=46798862

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013010335A MX351659B (en) 2011-03-09 2011-09-30 Non-aqueous high concentration reduced viscosity suspension formulations of antibodies.

Country Status (16)

Country Link
US (1) US20110223208A1 (en)
EP (1) EP2683403B1 (en)
JP (1) JP5881748B2 (en)
KR (1) KR101949707B1 (en)
CN (1) CN103402540A (en)
AU (1) AU2011361700B2 (en)
BR (1) BR112013023006A8 (en)
CA (1) CA2829367A1 (en)
EA (1) EA201391298A1 (en)
ES (1) ES2743687T3 (en)
IL (1) IL228211B (en)
MX (1) MX351659B (en)
SG (1) SG193278A1 (en)
UA (1) UA114289C2 (en)
WO (1) WO2012121754A1 (en)
ZA (2) ZA201307513B (en)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102869345B (en) 2010-03-17 2015-02-11 诺瓦利克有限责任公司 Pharmaceutical composition for treatment of increased intraocular pressure
EP2444063A1 (en) 2010-10-20 2012-04-25 Novaliq GmbH Liquid pharmaceutical compositions for the delivery of active ingredients
EP2462921A1 (en) 2010-11-11 2012-06-13 Novaliq GmbH Liquid pharmaceutical compositions for the treatment of a posterior eye disease
CN103442695B (en) 2011-03-10 2016-05-04 Xeris药物公司 The stabilization formulations of peptide medicine for parenteral injection
SG193963A1 (en) * 2011-04-07 2013-11-29 Glaxosmithkline Llc Formulations with reduced viscosity
PL3192501T3 (en) 2011-05-25 2020-11-02 Novaliq Gmbh Topical pharmaceutical composition based on semifluorinated alkanes
KR101989648B1 (en) 2012-01-23 2019-06-14 노바리크 게엠베하 Stabilised protein compositions based on semifluorinated alkanes
SG10201709555SA (en) * 2012-05-18 2017-12-28 Genentech Inc High-concentration monoclonal antibody formulations
JP2015519382A (en) * 2012-06-12 2015-07-09 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Pharmaceutical formulations for therapeutic antibodies
US9125805B2 (en) 2012-06-27 2015-09-08 Xeris Pharmaceuticals, Inc. Stable formulations for parenteral injection of small molecule drugs
ES2752034T3 (en) * 2012-07-17 2020-04-02 Bayer New Zealand Ltd Injectable antibiotic formations and their procedures for use
ES2965828T3 (en) 2012-09-12 2024-04-17 Novaliq Gmbh Semifluorinated alkane compositions
CA2883002C (en) 2012-09-12 2019-05-21 Novaliq Gmbh Compositions comprising mixtures of semifluorinated alkanes
JP2016515515A (en) * 2013-03-15 2016-05-30 バイエル・ヘルスケア・エルエルシーＢａｙｅｒ ＨｅａｌｔｈＣａｒｅ ＬＬＣ Anti-prolactin receptor antibody preparation
US10273298B2 (en) 2013-07-23 2019-04-30 Novaliq Gmbh Stabilized antibody compositions
EP3043775B1 (en) * 2013-09-11 2020-11-04 Eagle Biologics, Inc. Liquid protein formulations containing viscosity-lowering agents
PT2946765T (en) 2014-05-23 2016-11-10 Ares Trading Sa Liquid pharmaceutical composition
ES2607489T3 (en) 2014-05-23 2017-03-31 Ares Trading S.A. Liquid pharmaceutical composition
ES2572919T3 (en) 2014-05-23 2016-06-03 Ares Trading S.A. Liquid pharmaceutical composition
CA2952609A1 (en) * 2014-06-26 2015-12-30 Amgen Inc. Solid protein formulations comprising stabilizer, sugar alcohol, sugar and surfactant
AU2015300944B2 (en) * 2014-08-06 2019-07-11 Xeris Pharmaceuticals, Inc. Syringes, kits, and methods for intracutaneous and/or subcutaneous injection of pastes
US9649364B2 (en) 2015-09-25 2017-05-16 Xeris Pharmaceuticals, Inc. Methods for producing stable therapeutic formulations in aprotic polar solvents
JP6720293B2 (en) * 2015-08-19 2020-07-08 アストラゼネカ・アクチエボラーグＡｓｔｒａｚｅｎｅｃａ Ａｋｔｉｅｂｏｌａｇ Stable anti-IFNAR1 formulation
US11590205B2 (en) 2015-09-25 2023-02-28 Xeris Pharmaceuticals, Inc. Methods for producing stable therapeutic glucagon formulations in aprotic polar solvents
CN110403923B (en) 2015-09-30 2021-09-21 诺瓦利克有限责任公司 Semifluorinated compounds and compositions thereof
EP3722274B1 (en) 2015-09-30 2023-06-07 Novaliq GmbH 2-perfluorobutyl pentane for ophthalmic administration
DK3442480T3 (en) 2016-06-23 2020-01-13 Novaliq Gmbh PROCEDURE FOR TOPICAL SUBMISSION
ES2969758T3 (en) 2016-09-22 2024-05-22 Novaliq Gmbh Pharmaceutical compositions for use in the therapy of blepharitis
CN109906085B (en) 2016-09-23 2024-03-08 诺瓦利克有限责任公司 Ophthalmic compositions containing cyclosporin
US11459401B2 (en) 2016-10-06 2022-10-04 Amgen Inc. Reduced viscosity protein pharmaceutical formulations
CN108686205B (en) * 2017-04-07 2021-12-10 海正生物制药有限公司 Lyophilized preparation of infliximab
CN108686204A (en) * 2017-04-07 2018-10-23 浙江海正药业股份有限公司 Include the infliximab composition of histidine buffer system
AU2018253944B2 (en) 2017-04-21 2022-09-15 Dermaliq Therapeutics, Inc. Iodine compositions
EP3621601A1 (en) 2017-05-12 2020-03-18 Novaliq GmbH Pharmaceutical compositions comprosing semifluorinated alkanes for the treatment of contact lense-related conditions
CA3063324A1 (en) 2017-05-16 2018-11-22 Bhami's Research Laboratory, Pvt. Ltd. High concentration protein formulations with reduced viscosity
CN117085022A (en) 2017-06-02 2023-11-21 Xeris药物公司 Anti-precipitation small molecule pharmaceutical formulations
CN107167613B (en) * 2017-06-22 2018-10-02 深圳清华大学研究院 Albumen spotting buffer for plasma gold chip
US11723861B2 (en) 2017-09-27 2023-08-15 Novaliq Gmbh Ophthalmic compositions comprising latanoprost for use in the treatment of ocular diseases
US11896559B2 (en) 2017-10-04 2024-02-13 Novaliq Gmbh Opthalmic compositions comprising F6H8
SG11202007858VA (en) 2018-03-02 2020-09-29 Novaliq Gmbh Pharmaceutical compositions comprising nebivolol
EP3801469A4 (en) * 2018-06-07 2022-03-09 Merck Sharp & Dohme Corp. Lyosphere critical reagent kit
US20200061015A1 (en) * 2018-08-23 2020-02-27 Janssen Biotech, Inc. Lipase Degradation Resistant Surfactants for Use in Large Molecule Therapeutic Formulations
SG11202102820VA (en) 2018-10-12 2021-04-29 Novaliq Gmbh Ophthalmic composition for treatment of dry eye disease
WO2020106948A1 (en) * 2018-11-21 2020-05-28 Regeneron Pharmaceuticals, Inc. High concentration protein formulation
SG11202107901QA (en) 2019-02-05 2021-08-30 Lindy Biosciences Inc Isolated cell culture components and methods for isolating the same from liquid cell culture medium
CR20210435A (en) 2019-02-18 2021-09-20 Lilly Co Eli Therapeutic antibody formulation
JP2023503287A (en) * 2019-11-27 2023-01-27 ノバリック ゲーエムベーハー Suspension formulation containing protein particles suspended in non-aqueous solvent
CN113698478A (en) * 2020-05-21 2021-11-26 迈威(上海)生物科技股份有限公司 Anti-alpha-hemolysin antibody and stable formulation thereof

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3639587A (en) * 1969-11-07 1972-02-01 Eastman Kodak Co Medicinal compositions for administration to animals and process for administering same
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DE19638045A1 (en) * 1996-09-18 1998-03-19 Bayer Ag Injection formulations of avermectins and milbemycins
IN184589B (en) * 1996-10-16 2000-09-09 Alza Corp
US6169320B1 (en) 1998-01-22 2001-01-02 Raytheon Company Spiral-shaped inductor structure for monolithic microwave integrated circuits having air gaps in underlying pedestal
US7919109B2 (en) * 1999-02-08 2011-04-05 Intarcia Therapeutics, Inc. Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles
UA81743C2 (en) * 2000-08-07 2008-02-11 Центокор, Инк. HUMAN MONOCLONAL ANTIBODY WHICH SPECIFICALLY BINDS TUMOR NECROSIS FACTOR ALFA (TNFα), PHARMACEUTICAL MIXTURE CONTAINING THEREOF, AND METHOD FOR TREATING ARTHRITIS
DE60139944D1 (en) * 2000-10-12 2009-10-29 Genentech Inc LOW VISCOSIS CONCENTRATED PROTEIN FORMULATIONS
GB0113179D0 (en) * 2001-05-31 2001-07-25 Novartis Ag Organic compounds
AU2003227827B2 (en) * 2002-03-12 2008-09-25 Ethypharm Composition having gelling properties for the prolonged delivery of bioactive substances
WO2004089335A2 (en) 2003-03-31 2004-10-21 Alza Corporation Non-aqueous single phase vehicles and formulations utilizing such vehicles
DE10330235A1 (en) * 2003-07-04 2005-01-20 Bayer Healthcare Ag New Eimeria gene and protein as well as their use
US8728525B2 (en) * 2004-05-12 2014-05-20 Baxter International Inc. Protein microspheres retaining pharmacokinetic and pharmacodynamic properties
US20060141040A1 (en) 2004-12-23 2006-06-29 Guohua Chen Injectable non-aqueous suspension
US20060142234A1 (en) * 2004-12-23 2006-06-29 Guohua Chen Injectable non-aqueous suspension
EP2684895A1 (en) * 2006-10-27 2014-01-15 AbbVie Biotechnology Ltd Crystalline anti-hTNFalpha antibodies
WO2008092084A2 (en) * 2007-01-26 2008-07-31 Centocor, Inc. Injectable non-aqueous suspension with high concentration of therapeutic agent
US20090208492A1 (en) * 2007-06-14 2009-08-20 Elan Pharmaceuticals, Inc. Lyophilized Immunoglobulin Formulations and Methods of Preparation
US8563527B2 (en) * 2007-08-20 2013-10-22 Pharmain Corporation Oligonucleotide core carrier compositions for delivery of nucleic acid-containing therapeutic agents, methods of making and using the same
CA2743789C (en) * 2008-11-16 2017-10-31 Board Of Regents, The Univesity Of Texas System Low viscosity highly concentrated suspensions
CN103096934A (en) * 2010-03-09 2013-05-08 詹森生物科技公司 Non-aqueous high concentration reduced viscosity suspension formulations

Also Published As

Publication number Publication date
WO2012121754A1 (en) 2012-09-13
CA2829367A1 (en) 2012-09-13
JP5881748B2 (en) 2016-03-09
ZA201307513B (en) 2018-12-19
EP2683403B1 (en) 2019-06-19
BR112013023006A2 (en) 2016-12-06
AU2011361700B2 (en) 2017-06-22
UA114289C2 (en) 2017-05-25
IL228211B (en) 2018-04-30
AU2011361700A1 (en) 2013-09-19
SG193278A1 (en) 2013-10-30
EP2683403A4 (en) 2014-10-08
KR101949707B1 (en) 2019-02-19
US20110223208A1 (en) 2011-09-15
MX2013010335A (en) 2013-10-03
BR112013023006A8 (en) 2017-12-19
JP2014510077A (en) 2014-04-24
EA201391298A1 (en) 2014-02-28
KR20140145942A (en) 2014-12-24
ZA201600811B (en) 2016-11-30
ES2743687T3 (en) 2020-02-20
CN103402540A (en) 2013-11-20
EP2683403A1 (en) 2014-01-15

Similar Documents

Publication Publication Date Title
MX351659B (en) Non-aqueous high concentration reduced viscosity suspension formulations of antibodies.
PH12014501427B1 (en) Anti-phf-tau antibodies and their uses
PH12018500452A1 (en) Novel modulators and methods of use
MX2022000026A (en) Antibodies to tau.
PH12017501139A1 (en) Novel modulators and methods of use
PH12015502565A1 (en) Anti-transferrin receptor antibodies and methods of use
IN2014CN03887A (en)
MX342240B (en) Anti-fgfr4 antibodies and methods of use.
TN2013000378A1 (en) Anti - sclerostin antibody crystals and formulations thereof
MX2014002053A (en) Anti-mcsp antibodies.
IN2015DN00127A (en)
PH12015501059A1 (en) Anti-hemagglutinin antibodies and methods of use
MX2014004022A (en) ANTI-HtrA1 ANTIBODIES AND METHODS OF USE.
PH12014501605A1 (en) Anti-lrp5 antibodies and methods of use
MX346500B (en) Methods and compositions for neural disease immunotherapy.
IN2014CN03072A (en)
EP2544721A4 (en) Non-aqueous high concentration reduced viscosity suspension formulations
MX2013002960A (en) Antibody compositions and methods of use.

Legal Events

Date Code Title Description
HH Correction or change in general
FG Grant or registration